Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, European Medical Solutions's enterprise value is €31.04 Mil.
European Medical Solutions's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €4.85 Mil. Therefore, European Medical Solutions's EV-to-EBITDA for today is 6.41.
The historical rank and industry rank for European Medical Solutions's EV-to-EBITDA or its related term are showing as below:
STU:AS00'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -58.71 Med: -0.28 Max: 24.96
Current: 6.4
During the past 13 years, the highest EV-to-EBITDA of European Medical Solutions was 24.96. The lowest was -58.71. And the median was -0.28.
STU:AS00's EV-to-EBITDA is ranked better than 61.56% of 411
companies
in the Biotechnology industry
Industry Median: 12.78
vs STU:AS00: 6.40
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
European Medical Solutions (STU:AS00) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
European Medical Solutions's PE Ratio (TTM) for today is calculated as:
European Medical Solutions's share price for today is €3.94.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. European Medical Solutions's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.435.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:AS00 vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, European Medical Solutions's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
European Medical Solutions EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, European Medical Solutions's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where European Medical Solutions's EV-to-EBITDA falls into.
European Medical Solutions's current Enterprise Value is €31.04 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. European Medical Solutions's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €4.85 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
European Medical Solutions (STU:AS00) has a EV-to-EBITDA of 6.41 as of Aug. 05, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on European Medical Solutions. According to the industry distribution chart, European Medical Solutions ranks #158 out of 411 companies in the Biotechnology industry, placing it in the top 38.4%.
Is European Medical Solutions' EV-to-EBITDA too high?
European Medical Solutions' current EV-to-EBITDA is 6.41. The Biotechnology industry median EV-to-EBITDA is 12.78. European Medical Solutions' value of 6.41 is 49.8% below this industry median. Based on the distribution chart, European Medical Solutions ranks #158 out of 411 companies in the Biotechnology industry, which is above the industry midpoint. Overall, European Medical Solutions has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does European Medical Solutions' EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, European Medical Solutions ranks #158 out of 411 companies for EV-to-EBITDA. This puts European Medical Solutions in the upper half of its industry. The industry median EV-to-EBITDA is 12.78. European Medical Solutions' value of 6.41 is 49.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.78, based on 411 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. European Medical Solutions's current EV-to-EBITDA of 6.41 is 49.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on European Medical Solutions. For the Biotechnology industry, the median EV-to-EBITDA is 12.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. European Medical Solutions's current EV-to-EBITDA is 6.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is European Medical Solutions stock overvalued right now?
Based on GuruFocus' analysis, European Medical Solutions (STU:AS00) is currently considered Possible Value Trap. The stock's GF Value™ is €7.43, compared to a current price of €3.94 — trading 47% below its estimated fair value. The current EV-to-EBITDA is 6.41 and 49.8% below the Biotechnology industry median of 12.78. European Medical Solutions' overall GF Score™ is 51/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For European Medical Solutions (STU:AS00), the current EV-to-EBITDA is 6.41 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is European Medical Solutions (STU:AS00) Overvalued in 2026?
Based on GuruFocus' analysis, European Medical Solutions stock appears to be undervalued.
The current stock price of €3.94 is trading 47% below its estimated GF Value™ of €7.43.
GuruFocus considers European Medical Solutions to be Possible Value Trap.
Key valuation signals for STU:AS00:
EV-to-EBITDA: 6.41
GF Value™: €7.43 vs. price of €3.94 (47% below fair value)
Industry Position: 49.8% below the Biotechnology median (#158 of 411)
No single metric tells the full story. See the STU:AS00 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
European Medical Solutions Formerly DMS Imaging SA is a clinical-stage biopharmaceutical company. The company is engaged in the development and future commercialization of a range of breakthrough immunotherapy products for the treatment of allergies, based on its ASIT+ technology platform. Its lead product is gp-ASIT+, a phase III trial for the treatment of grass pollen rhinitis. Its pipeline products consist of hdm-ASIT+ for the treatment of house dust mite asthma; and pnt-ASIT+ for the treatment of peanut allergy.
51GF Score
Get the complete analysis for STU:AS00
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:AS00 has been successfully added to your 
